EIF3A and hepatocellular carcinoma: Recent research has shown that is aberrantly overexpressed in HCC, is associated with poor prognosis, promotes tumorigenesis by regulating eIF3a/b expression, and could be a potential new target for HCC therapy (Su et al., 2022).